Published 19 May 2009, doi:10.1136/bmj.b1665
Cite this as: BMJ 2009;338:b1665

Research

Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies

¹ Centre for Environmental and Preventive Medicine, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine, Queen Mary University of London, London EC1M 6BQ

Objectives To determine the quantitative efficacy of different classes of blood pressure lowering drugs in preventing coronary heart disease (CHD) and stroke, and who should receive treatment.

Design Meta-analysis.

Data source Medline (1966-2007).

Study selection Randomised trials of blood pressure lowering drugs recording CHD events and strokes. 108 trials studied differences in blood pressure between study drug and placebo (or control group not receiving the study drug) ("blood pressure difference trials"), and 46 trials compared drugs ("drug comparison trials"). Seven trials with three randomised groups fell into both categories. The results were interpreted in the context of those expected from the largest published meta-analysis of cohort studies, totalling 958 000 people.

Participants 464 000 people defined into three mutually exclusive categories: participants with no history of vascular disease, a history of CHD, or a history of stroke.

Results In the blood pressure difference trials β blockers had a special effect over and above that due to blood pressure reduction in preventing recurrent CHD events in people with a history of CHD: risk reduction 29% (95% confidence interval 22% to 34%) compared with 15% (11% to 19%) in trials of other drugs. The extra effect was limited to a few years after myocardial infarction, with a risk reduction of 31% compared with 13% in people with CHD with no recent infarct (P=0.04). In the other blood pressure difference trials (excluding CHD events in trials of β blockers in people with CHD), there was a 22% reduction in CHD events (17% to 27%) and a 41% (33% to 48%) reduction in stroke for a blood pressure reduction of 10 mm Hg systolic or 5 mm Hg diastolic, similar to the reductions of 25% (CHD) and 36% (stroke) expected for the same difference in blood pressure from the cohort study meta-analysis, indicating that the benefit is explained by blood pressure reduction itself. The five main classes of blood pressure lowering drugs (thiazides, β blockers, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and calcium channel blockers) were similarly effective (within a few percentage points) in preventing CHD events and strokes, with the exception that calcium channel blockers had a greater preventive effect on stroke (relative risk 0.92, 95% confidence interval 0.85 to 0.98). The percentage reductions in CHD events and stroke were similar in people with and without cardiovascular disease and regardless of blood pressure before treatment (down to 110 mm Hg systolic and 70 mm Hg diastolic). Combining our results with those from two other studies (the meta-analyses of blood pressure cohort studies and of trials determining the blood pressure lowering effects of drugs according to dose) showed that in people aged 60-69 with a diastolic blood pressure before treatment of 90 mm Hg, three drugs at half standard dose in combination reduced the risk of CHD by an estimated 46% and of stroke by 62%; one drug at standard dose had about half this effect. The present meta-analysis also showed that drugs other than calcium channel blockers (with the exception of non-cardioselective β blockers) reduced the incidence of heart failure by 24% (19% to 28%) and calcium channel blockers by 19% (6% to 31%).

Conclusions With the exception of the extra protective effect of β blockers given shortly after a myocardial infarction and the minor additional effect of calcium channel blockers in preventing stroke, all the classes of blood pressure lowering drugs have a similar effect in reducing CHD events and stroke for a given reduction in blood pressure so excluding material pleiotropic effects. The proportional reduction in cardiovascular disease events was the same or similar regardless of pretreatment blood pressure and the presence or absence of existing cardiovascular disease. Guidelines on the use of blood pressure lowering drugs can be simplified so that drugs are offered to people with all levels of blood pressure. Our results indicate the importance of lowering blood pressure in everyone over a certain age, rather than measuring it in everyone and treating it in some.

© Law et al 2009
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Contradicting Cochrane

Ray F O’Connor and Ruth Moloney
BMJ 2009 339: b3997. [Extract] [Full Text]

Law’s flaw?

L Sam Lewis
BMJ 2009 338: b2596. [Extract] [Full Text]

All cause absolute benefit?

Patrick Bower
BMJ 2009 338: b2597. [Extract] [Full Text]

Best use of resources?

Anthony N Glaser
BMJ 2009 338: b2598. [Extract] [Full Text]

Assumptions and extrapolation

Sripal Bangalore and Franz H Messerli
BMJ 2009 338: b2600. [Extract] [Full Text]

Up to a point

Michael Schachter
BMJ 2009 338: b2601. [Extract] [Full Text]

Authors’ reply

Malcolm Law, Joan K Morris, and Nicholas Wald
BMJ 2009 338: b2602. [Extract] [Full Text]

Home monitoring, a way to go?

Joao Calinas-Correia
BMJ 2009 338: b2623. [Extract] [Full Text]

QOF and whistleblowers

Jane Smith
BMJ 2009 338: b2263. [Extract] [Full Text]

A new era for blood pressure management

Fiona Godlee
BMJ 2009 338: b2068. [Extract] [Full Text]

Management of blood pressure in primary care

Richard J McManus and Jonathan Mant
BMJ 2009 338: b940. [Extract] [Full Text]

Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials

Blood Pressure Lowering Treatment Trialists’ Collaboration
BMJ 2008 336: 1121-1123. [Abstract] [Full Text] [PDF]

Angiotensin receptor blockers and myocardial infarction

Subodh Verma and Marty Strauss
BMJ 2004 329: 1248-1249. [Extract] [Full Text] [PDF]

British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary

Bryan Williams, Neil R Poulter, Morris J Brown, Mark Davis, Gordon T McInnes, John F Potter, Peter S Sever, and Simon McG Thom
BMJ 2004 328: 634-640. [Extract] [Full Text] [PDF]

Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials

M R Law, N J Wald, J K Morris, and R E Jordan
BMJ 2003 326: 1427. [Abstract] [Full Text] [PDF]

Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis

M R Law, N J Wald, and A R Rudnicka
BMJ 2003 326: 1423. [Abstract] [Full Text] [PDF]

PubMed Central: creating an Aladdin's cave of ideas

Tony Delamothe and Richard Smith
BMJ 2001 322: 1-2. [Extract] [Full Text] [PDF]

Related external webpages:

Listen to a podcast interview with Professor Malcolm Law about the proposed polypill

This article has been cited by other articles:

• O'Connor, R. F, Moloney, R. (2009). Contradicting Cochrane. BMJ 339: b3997-b3997 [Full text]  
• Vasan, R. S., Kannel, W. B. (2009). Strategies for Cardiovascular Risk Assessment and Prevention Over the Life Course: Progress Amid Imperfections. Circulation 120: 360-363 [Full text]  
• Lewis, L S. (2009). Law's flaw?. BMJ 338: b2596-b2596 [Full text]  
• Bower, P. (2009). All cause absolute benefit?. BMJ 338: b2597-b2597 [Full text]  
• Glaser, A. N (2009). Best use of resources?. BMJ 338: b2598-b2598 [Full text]  
• Bangalore, S., Messerli, F. H (2009). Assumptions and extrapolation. BMJ 338: b2600-b2600 [Full text]  
• Schachter, M. (2009). Up to a point. BMJ 338: b2601-b2601 [Full text]  
• Law, M., Morris, J. K, Wald, N. (2009). Authors' reply. BMJ 338: b2602-b2602 [Full text]  
• Calinas-Correia, J. (2009). Home monitoring, a way to go?. BMJ 338: b2623-b2623 [Full text]  
• (2009). BP-Lowering Drugs and Prevention of Cardiovascular Disease. JWatch General 2009: 1-1 [Full text]  
• McManus, R. J, Mant, J. (2009). Management of blood pressure in primary care. BMJ 338: b940-b940 [Full text]  

Rapid Responses:

Read all Rapid Responses

Lowering blood pressure for secondary stroke prevention

Rizaldy Pinzon
bmj.com, 20 May 2009 [Full text]

Fire and Forget ? not just yet

L Sam Lewis
bmj.com, 21 May 2009 [Full text]

Blood pressure and Numbers Needlessly Treated

Eddie Vos
bmj.com, 21 May 2009 [Full text]

Prehypertension

Leonard Gehl
bmj.com, 23 May 2009 [Full text]

All cause absoute benefit, please.

Patrick Bower
bmj.com, 24 May 2009 [Full text]

Re: All cause absoute benefit, please.

Harry Hall
bmj.com, 25 May 2009 [Full text]

Up to a point

Michael Schachter
bmj.com, 25 May 2009 [Full text]

Impressive and provocative, but . . .

Anthony N Glaser
bmj.com, 25 May 2009 [Full text]

women and serious adverse events data

Maryann Napoli
bmj.com, 26 May 2009 [Full text]

Recognising the effects of blood pressure-lowering drugs.

Leslie O Simpson
bmj.com, 26 May 2009 [Full text]

Pharma marketing dream

Aaron Hollins
bmj.com, 26 May 2009 [Full text]

doctor Knock

pietro cavalli
bmj.com, 26 May 2009 [Full text]

Lowering blood pressure.

Susan E Hand
bmj.com, 28 May 2009 [Full text]

What disease was being treated?

Richard G Fiddian-Green
bmj.com, 29 May 2009 [Full text]

A global approach is needed: new analyses are needed.

Vivencio Barrios, et al.
bmj.com, 29 May 2009 [Full text]

Of Assumptions, Potpourri and Sausages

Sripal Bangalore, et al.
bmj.com, 29 May 2009 [Full text]

Lowering blood pressure without drugs

Evan L Lloyd
bmj.com, 31 May 2009 [Full text]

Time to Treat Blood Pressure as a Risk Factor, Not a Disease

Dr John S Ashcroft
bmj.com, 1 Jun 2009 [Full text]

Blood pressure drugs or lifestyle changes?

andrew w wijnberg
bmj.com, 1 Jun 2009 [Full text]

What are the quantitative effect of taking one or more blood pressure lowering drugs on blood pressure and the risk of CHD events and stroke?

Óscar Mota
bmj.com, 1 Jun 2009 [Full text]

Re: Lowering blood pressure without drugs

Leslie O Simpson
bmj.com, 1 Jun 2009 [Full text]

The Tyrrany of the Mean

Graham Kyle
bmj.com, 1 Jun 2009 [Full text]

Re: Blood pressure drugs or lifestyle changes?

Les O. Simpson
bmj.com, 2 Jun 2009 [Full text]

Beta-blockers in the treatment of hypertension

John M Cruickshank
bmj.com, 10 Jun 2009 [Full text]

Two inconsistencies and one omission in the comparisons of antihypertensive drugs

Alberto Donzelli
bmj.com, 11 Jun 2009 [Full text]

Beta-blockers and hypertension revisited

Bo Carlberg, et al.
bmj.com, 15 Jun 2009 [Full text]

Bulls eye!

david leopold
bmj.com, 16 Jun 2009 [Full text]

Reply to rapid responses on bmj.com

Malcolm Law, et al.
bmj.com, 26 Jun 2009 [Full text]

Law's Floor :- re: Reply to rapid responses on bmj.com

L Sam Lewis
bmj.com, 27 Jun 2009 [Full text]

Artificial and real dichotomies

Michael Power
bmj.com, 27 Jun 2009 [Full text]

Law, Morris and Wald: answer the question.

Richard G Fiddian-Green
bmj.com, 28 Jun 2009 [Full text]

Not the polypill but the roly-poly pill

Paul A Corwin
bmj.com, 14 Jul 2009 [Full text]

Re: Reply to rapid responses on bmj.com

Les O. Simpson
bmj.com, 15 Jul 2009 [Full text]

The importance of a pathophysiology.

Leslie O Simpson
bmj.com, 21 Jul 2009 [Full text]

Blood pressure lowering in haemophiliacs

Jerzy Windyga, et al.
bmj.com, 28 Jul 2009 [Full text]

Contradicting Cochrane

Ray F O'Connor, et al.
bmj.com, 27 Sep 2009 [Full text]

A cheap pill to prevent heart disease globally?

M Justin S Zaman
bmj.com, 25 Oct 2009 [Full text]

Online poll

Find out more on doc2doc >>